Compare RAMP & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAMP | NVAX |
|---|---|---|
| Founded | 2018 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 1994 | 1996 |
| Metric | RAMP | NVAX |
|---|---|---|
| Price | $37.41 | $8.53 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 9 |
| Target Price | ★ $35.60 | $11.33 |
| AVG Volume (30 Days) | 1.8M | ★ 4.4M |
| Earning Date | 05-20-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22500.00 | 309.76 |
| EPS | ★ 2.24 | N/A |
| Revenue | $812,940,000.00 | ★ $1,123,479,000.00 |
| Revenue This Year | $11.18 | N/A |
| Revenue Next Year | $9.09 | N/A |
| P/E Ratio | $16.71 | ★ N/A |
| Revenue Growth | 9.03 | ★ 64.69 |
| 52 Week Low | $21.71 | $6.20 |
| 52 Week High | $37.92 | $11.85 |
| Indicator | RAMP | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 68.08 | 40.85 |
| Support Level | $37.24 | $7.94 |
| Resistance Level | $37.92 | $9.02 |
| Average True Range (ATR) | 0.20 | 0.63 |
| MACD | -0.32 | -0.09 |
| Stochastic Oscillator | 23.13 | 13.40 |
LiveRamp Holdings Inc is a technology company that helps companies build enduring brand and business value by collaborating responsibly with data. A groundbreaking leader in consumer privacy, data ethics, and foundational identity, LiveRamp offers a connected customer view with clarity and context while protecting brand and consumer trust. The Company provides a data collaboration platform, essentially acting as a data collaboration hub where businesses can securely share and manage first-party consumer data with trusted partners while prioritizing data privacy and ethics.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.